Tumor Types News Today : Breaking News, Live Updates & Top Stories | Vimarsana

much for the latest. >> it's the top of the hour on cnn newsroom. i'm alisyn camerota. >> i'm victor blackwell. we start this hour with the tears and the grief and the stories of terror from capitol hill today as people who have been deeply impacted by america's latest mass shootings testify to the house oversight committee. the youngest voice, just 11 years old, a 4th grader who survived the massacre in uvalde, texas. >> recounting the worst moments that she endured 77 minutes of living hell. she had to play dead. she had to smear her best friend's blood on her to hide from a gunman...

Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models.

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec

Dublin, Aug. 07, 2023 (GLOBE NEWSWIRE) -- The "PEComa - Market Insights, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides in-depth insights into PEComa, including historical and forecasted epidemiology, market trends, and treatment practices in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Market Assessment: The report covers current treatment practices, emerging drugs, market sha

Tried before? what makes it such a game changer? >> so it's interesting. this is a therapy that in the late 2010s, early 2010s, started creeping up for the treatment of lung cancer and melanoma and then kidney cancers and then we started seeing pockets of other diseases where immunotherapy called check point blockade therapy was highly effective, and it's really been a game changer for patients with metastatic disease, with those certain tumor types. we decided to move it to early stage disease, where normally a surgery was required to cure the patient. instead of doing a surgery, we gave this...